2018
DOI: 10.1039/c7sc04761d
|View full text |Cite
|
Sign up to set email alerts
|

L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib

Abstract: Impact of L718Q mutation on the inhibitory activity of osimertinib on EGFR revealed by free-energy simulations.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
84
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
8
2

Relationship

1
9

Authors

Journals

citations
Cited by 81 publications
(87 citation statements)
references
References 55 publications
3
84
0
Order By: Relevance
“…Generally, in practical investigations of reactivity, relative barriers (rather than absolute barriers) are important, 111, 112 e.g. to distinguish between possible mechanisms, to identify reactive conformations 113,114 , predict the effects of mutation, reactivity of alternative substrates or analyse chemo-, stereo-or regioselectivity. [101][102][103][104] However, limitations of DFT may prevent reliable predictions even for calculations of relative barriers.…”
Section: Acs Paragon Plus Environmentmentioning
confidence: 99%
“…Generally, in practical investigations of reactivity, relative barriers (rather than absolute barriers) are important, 111, 112 e.g. to distinguish between possible mechanisms, to identify reactive conformations 113,114 , predict the effects of mutation, reactivity of alternative substrates or analyse chemo-, stereo-or regioselectivity. [101][102][103][104] However, limitations of DFT may prevent reliable predictions even for calculations of relative barriers.…”
Section: Acs Paragon Plus Environmentmentioning
confidence: 99%
“…Remarkably, in vitro analysis suggests that the L718Q T790M double mutant re-sensitizes the receptor to afatinib [93]. Molecular modeling shows that the L718Q mutation appears to block osimertinib from interacting covalently with C797 [94]. Finally, a L747P mutation [95] also renders cells resistant to osimertinib while sensitizing cells to afatinib [96,97].…”
Section: Epidermal Growth Factor Receptor (Egfr)mentioning
confidence: 99%
“…72,78,79 The statistical error was estimated by averaging the free energy difference between 10-20 ps and 20-30 ps. 80,81 The QM/MM boundary was treated by the pseudo-bond approach 77,82,83 with the improved parameters. 84 All other atoms were described by the same molecular mechanical force eld used in classical MD simulations.…”
Section: Setup For Qm/mm MD Simulationsmentioning
confidence: 99%